{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:19:03Z","timestamp":1785856743774,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1208\/s12248-016-9891-4","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T22:16:47Z","timestamp":1456352207000},"page":"573-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling"],"prefix":"10.1208","volume":"18","author":[{"given":"Robert N.","family":"Schuck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"9891_CR1","unstructured":"Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. The National Academies Collection: Reports funded by national institutes of health. Washington (DC) 2011."},{"key":"9891_CR2","unstructured":"U.S. Food and Drug Administration: Paving the way for personalized medicine. Accessed from http:\/\/www.Fda.Gov\/downloads\/scienceresearch\/specialtopics\/personalizedmedicine\/ucm372421.Pdf . 2013."},{"issue":"3","key":"9891_CR3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ncponc1303","volume":"6","author":"CM Walko","year":"2009","unstructured":"Walko CM, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol. 2009;6(3):153\u201362.","journal-title":"Nat Clin Pract Oncol"},{"key":"9891_CR4","first-page":"99","volume":"8","author":"A Agarwal","year":"2015","unstructured":"Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Curr Pharmgenomics Pers Med. 2015;8:99\u2013110.","journal-title":"Curr Pharmgenomics Pers Med"},{"issue":"2\u20133","key":"9891_CR5","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.ddstr.2011.04.002","volume":"9","author":"MA Pacanowski","year":"2012","unstructured":"Pacanowski MA, Zineh I. Pharmacogenomic strategies in drug safety. Drug Discov Today Ther Strategy. 2012;9(2\u20133):e67\u201374.","journal-title":"Drug Discov Today Ther Strategy"},{"issue":"4","key":"9891_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1479-7364-4-4-221","volume":"4","author":"I Zineh","year":"2010","unstructured":"Zineh I, Woodcock J. The clinical pharmacogeneticist: an emerging regulatory scientist at the us food and drug administration. Hum Genomics. 2010;4(4):221\u20135.","journal-title":"Hum Genomics"},{"key":"9891_CR7","doi-asserted-by":"crossref","unstructured":"Food and drugs, 21 c.F.R. \u00a7 201.56 (2010).","DOI":"10.1017\/S0570608410000050"},{"key":"9891_CR8","unstructured":"U.S. Food and Drug Administration: Guidance for industry\u2014clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Accessed from http:\/\/www.Fda.Gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm337169.Pdf . 2013."},{"key":"9891_CR9","unstructured":"U.S. Food and Drug Administration: Guidance for industry\u2014safety labeling changes\u2014implementation of section 505(o)(4) of the fd&c act. Accessed from http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm250783.pdf . 2013."},{"issue":"8","key":"9891_CR10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1592\/phco.31.8.729","volume":"31","author":"I Zineh","year":"2011","unstructured":"Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy. 2011;31(8):729\u201335.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"9891_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/clpt.2013.222","volume":"95","author":"MA Pacanowski","year":"2014","unstructured":"Pacanowski MA, Leptak C, Zineh I. Next-generation medicines: past regulatory experience and considerations for the future. Clin Pharmacol Ther. 2014;95(3):247\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"9891_CR12","unstructured":"U.S. Food and Drug Administration: Draft guidance for industry\u2014enrichment strategies for clinical trials to support approval of human drugs and biological products. Accessed from http:\/\/www.Fda.Gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm332181.Pdf . 2012."},{"issue":"8","key":"9891_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9891_CR14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920021503140412212905","volume":"15","author":"S Shi","year":"2014","unstructured":"Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271\u201390.","journal-title":"Curr Drug Metab"},{"issue":"12","key":"9891_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/jir.2012.0136","volume":"34","author":"GS Pandey","year":"2014","unstructured":"Pandey GS, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. J Interferon Cytokine Res. 2014;34(12):931\u20137.","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"9891_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4155\/tde.10.101","volume":"2","author":"C Grimstein","year":"2011","unstructured":"Grimstein C, Bai JP. Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. Ther Deliv. 2011;2(3):369\u201381.","journal-title":"Ther Deliv"},{"issue":"4","key":"9891_CR17","first-page":"403","volume":"12","author":"VL Simhadri","year":"2015","unstructured":"Simhadri VL, Banerjee AS, Simon J, Kimchi-Sarfaty C, Sauna ZE. Personalized approaches to the treatment of hemophilia A and B. Perinat Med. 2015;12(4):403\u201315.","journal-title":"Perinat Med"},{"issue":"2","key":"9891_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","volume":"1","author":"P Carter","year":"2001","unstructured":"Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118\u201329.","journal-title":"Nat Rev Cancer"},{"key":"9891_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","volume":"6","author":"JD Mellor","year":"2013","unstructured":"Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"9891_CR20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","volume":"19","author":"E Louis","year":"2004","unstructured":"Louis E, El Ghoul Z, Vermeire S, Dall\u2019Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IGG FC receptor IIIA coding gene and biological response to infliximab in Crohn\u2019s disease. Aliment Pharmacol Ther. 2004;19(5):511\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"9891_CR21","unstructured":"U.S. Food and Drug Administration: Annual novel new drugs summary. Accessed from http:\/\/www.Fda.Gov\/downloads\/drugs\/developmentapprovalprocess\/druginnovation\/ucm430299.Pdf . 2014."},{"issue":"2","key":"9891_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00063030-200620020-00001","volume":"20","author":"PD Maher","year":"2006","unstructured":"Maher PD, Haffner M. Orphan drug designation and pharmacogenomics: options and opportunities. BioDrugs. 2006;20(2):71\u20139.","journal-title":"BioDrugs"},{"key":"9891_CR23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/2168479015580383","volume":"49","author":"FJ Sasinowski","year":"2015","unstructured":"Sasinowski FJ, Panico EB, Valentine JE. Quantum of effectiveness evidence in FDA\u2019s approval of orphan drugs: update, July 2010 to June 2014. Ther Innov Regul Sci. 2015;49:680\u201397.","journal-title":"Ther Innov Regul Sci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-016-9891-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9891-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T23:24:54Z","timestamp":1567639494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-016-9891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["9891"],"URL":"https:\/\/doi.org\/10.1208\/s12248-016-9891-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]}}}